Poly(ADP-ribose) Polymerase Inhibitors
"Poly(ADP-ribose) Polymerase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals and drugs that inhibit the action of POLY(ADP-RIBOSE)POLYMERASES.
| Descriptor ID |
D000067856
|
| MeSH Number(s) |
D27.505.519.389.739 D27.505.954.248.692
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Poly(ADP-ribose) Polymerase Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Poly(ADP-ribose) Polymerase Inhibitors".
This graph shows the total number of publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in this website by year, and whether "Poly(ADP-ribose) Polymerase Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2009 | 1 | 1 | 2 |
| 2014 | 2 | 2 | 4 |
| 2015 | 1 | 0 | 1 |
| 2017 | 2 | 1 | 3 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
| 2023 | 1 | 1 | 2 |
| 2024 | 0 | 2 | 2 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Poly(ADP-ribose) Polymerase Inhibitors" by people in Profiles.
-
PARP inhibitor response is enhanced in prostate cancer when XRCC1 expression is reduced. NAR Cancer. 2025 Jun; 7(2):zcaf015.
-
Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clin Cancer Res. 2025 Mar 17; 31(6):975-982.
-
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors. CA Cancer J Clin. 2025 Mar-Apr; 75(2):141-167.
-
PARP inhibition radiosensitizes BRCA1 wildtype and mutated breast cancer to proton therapy. Sci Rep. 2024 12 28; 14(1):30897.
-
Homologous recombination deficiency in ovarian cancer: Global expert consensus on testing and a comparison of companion diagnostics. Eur J Cancer. 2025 Jan 17; 215:115169.
-
UBA1 inhibition sensitizes cancer cells to PARP inhibitors. Cell Rep Med. 2024 Dec 17; 5(12):101834.
-
Racial and sociodemographic disparities in the use of targeted therapies in advanced ovarian cancer patients with Medicare. Int J Gynecol Cancer. 2024 11 04; 34(11):1661-1670.
-
Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial. Target Oncol. 2024 Nov; 19(6):879-892.
-
Patient-reported Outcomes for Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1/2 Gene Alterations: Final Analysis from the Randomized Phase 3 MAGNITUDE Trial. Eur Urol. 2025 Oct; 88(4):359-369.
-
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021. Gynecol Oncol. 2024 Nov; 190:255-261.